J. Fischel

发表

Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel–erlotinib and 5-fluoro-5′-deoxyuridine

G. Milano, J. Fischel, J. Ciccolini, 2006, Anti-cancer drugs.

Pharmacological background of EGFR targeting.

N. Magné, G. Milano, M. Etienne-Grimaldi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

G Milano, N. Magné, P. Laurent-Puig, 2002, British Journal of Cancer.

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer

G Milano, N. Magné, A. Dubreuil, 2002, British Journal of Cancer.

Emerging molecular targeted therapies in the treatment of head and neck cancer

A. Bozec, G. Milano, J. Fischel, 2009, Expert opinion on emerging drugs.

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126

A. Bozec, G. Milano, J. Gugenheim, 2006, British Journal of Cancer.

Epidermal growth factor receptor expression and suramin cytotoxicity in vitro.

G. Milano, J. Fischel, P. Formento, 1990, European journal of cancer.

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors

G Milano, G. Milano, J. Fischel, 2005, British Journal of Cancer.

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

O. Dassonville, F. Demard, G. Milano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2011, Oral oncology.

Establishment, characterization, and response to cytotoxic and radiation treatment of three human melanoma cell lines

A. Courdi, F. Ettore, J. Fischel, 1983, In Vitro.

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2008, British Journal of Cancer.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

G. Milano, M. Merlano, M. Etienne-Grimaldi, 2013, Urologic oncology.

Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience

A. Bozec, G. Milano, J. Fischel, 2006, Current opinion in oncology.

Oxaliplatin–5-Fluorouracil and Ionizing Radiation

N. Magné, A. Dubreuil, S. Marcié, 2003, Oncology.

Lack of contribution of dihydrofluorouracil and &agr;-fluoro-&bgr;-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes

G. Milano, M. Etienne-Grimaldi, J. Fischel, 2004, Anti-cancer drugs.

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid

G. Milano, J. Bérille, J. Fischel, 2004, Cancer Chemotherapy and Pharmacology.

Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

J. Formento, G. Milano, J. Fischel, 1998, Biochemical pharmacology.

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity

G. Milano, J. Fischel, J. Ciccolini, 2002, British Journal of Cancer.

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.

F. Penault-Llorca, A. Bozec, G. Milano, 2008, European journal of cancer.

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.

G. Milano, J. Fischel, P. Formento, 1997, European journal of cancer.

Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.

F. Demard, J. Santini, G. Milano, 1991, British Journal of Cancer.

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

G. Milano, J. Fischel, P. Formento, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study

G. Milano, M. Merlano, M. Etienne-Grimaldi, 2013, Investigational New Drugs.

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis

A. Dubreuil, G. Milano, J. Fischel, 2001, British Journal of Cancer.

Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines.

G. Milano, J. Fischel, P. Formento, 1993, European journal of cancer.

Steroid receptors in human osteoblast-like cells.

M. Namer, G. Milano, J. Fischel, 1990, European journal of cancer.

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

G. Milano, J. Fischel, P. Formento, 1994, European journal of cancer.

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.

G. Milano, J. Fischel, P. Formento, 1997, Biochemical pharmacology.

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2010, Oral oncology.

Inhibition of dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines

L. Thill, G. Milano, J. Fischel, 2004, Cancer Chemotherapy and Pharmacology.

Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile.

M. Namer, G. Milano, J. Fischel, 1992, European journal of cancer.

Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.

G. Milano, J. Fischel, P. Formento, 1993, European journal of cancer.

Impact of erythropoietin on the effects of irradiation under hypoxia

G. Milano, P. Catarsi, M. Merlano, 2009, Journal of Cancer Research and Clinical Oncology.

Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation.

G. Milano, M. Etienne-Grimaldi, J. Fischel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative study of the 16S RNA's of Escherichia coli and Proteus vulgaris.

J. Ebel, C. Ehresmann, A. Krol, 1975, Biochimie.

A comparison of the primary structures of the 16 S ribosomal RNAs from Escherichia coli and Proteus vulgaris

J. Ebel, J. Fischel, P. Fellner, 1970, FEBS letters.

Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment.

F. Demard, A. Courdi, F. Ettore, 1988, European journal of cancer & clinical oncology.

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase

G. Milano, J. Fischel, P. Formento, 1996, Cancer Chemotherapy and Pharmacology.

Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them.

G. Milano, J. Fischel, P. Formento, 1994, European journal of cancer.

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.

G. Milano, J. Fischel, P. Formento, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.

G. Milano, J. Fischel, P. Formento, 1994, European journal of cancer.

[Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].

G. Milano, J. Fischel, P. Formento, 1994, Bulletin du Cancer.

Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine).

G. Milano, J. Fischel, P. Formento, 1993, European journal of cancer.

Cell growth inhibitory effects of caulerpenyne, a sesquiterpenoid from the marine algae Caulerpa taxifolia.

A. Meinesz, J. Fischel, P. Formento, 1995, Anticancer research.

In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea

G. Milano, J. Fischel, P. Formento, 2004, Cancer Chemotherapy and Pharmacology.

Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.

N. Magné, G. Milano, J. Peyron, 2001, Cancer research.

Activation of Nuclear Factor κB through the IKK Complex by the Topoisomerase Poisons SN38 and Doxorubicin: A Brake to Apoptosis in HeLa Human Carcinoma Cells

N. Magné, G. Milano, J. Peyron, 2001 .

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.

G. Milano, J. Gugenheim, M. Etienne-Grimaldi, 2005, European journal of cancer.

Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.

N. Magné, G. Milano, M. Etienne-Grimaldi, 2004, European journal of cancer.

Establishment, characterization, chemosensitivity, and radiosensitivity of two different cell lines derived from a human breast cancer biopsy.

M. Namer, A. Courdi, F. Ettore, 1985, Cancer research.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

G. Pagès, G. Milano, M. Merlano, 2013, Urologic oncology.

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

G. Milano, P. Hofman, M. Merlano, 2007, Journal of Cancer Research and Clinical Oncology.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

P. Laurent-Puig, J. Formento, G. Milano, 2004, British Journal of Cancer.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

A. Bozec, O. Dassonville, G. Milano, 2007, Critical reviews in oncology/hematology.

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment

A. Bozec, G. Milano, J. Fischel, 2010, Pharmaceuticals.

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.

G. Pagès, G. Milano, R. Largillier, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

The combination of docetaxel and the somatostatin analogue lanreotide on androgen‐independent docetaxel‐resistant prostate cancer: experimental data

G. Milano, M. Merlano, J. Fischel, 2008, BJU international.

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

N. Magné, A. Dubreuil, J. Formento, 2003, British Journal of Cancer.

Tamoxifen metabolism: pharmacokinetic and in vitro study.

M. Namer, J. Formento, G. Milano, 1989, British Journal of Cancer.

Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

G. Milano, J. Fischel, P. Formento, 1991, British Journal of Cancer.

Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities.

G. Milano, J. Fischel, P. Formento, 1993, Biochemical pharmacology.

Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer

M. Namer, G. Milano, J. Fischel, 2005, Breast Cancer Research and Treatment.

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants

G. Milano, A. Iliadis, J. Fischel, 2012, Fundamental & clinical pharmacology.

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

N. Magné, A. Dubreuil, G. Milano, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines.

G. Milano, J. Fischel, P. Formento, 1999, Anti-Cancer Drugs.

Emergingmoleculartargeted therapiesinthetreatmentof headandneckcancer

A. Bozec, G. Milano, J. Fischel, 2009 .

Taxotere–5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells

Joseph Ciccolini, G Milano, G. Milano, 2005, Anti-cancer drugs.

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

G Milano, A. Dubreuil, G. Milano, 2001, British Journal of Cancer.

Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines

G. Milano, J. Fischel, J. Ciccolini, 2010, Journal of chemotherapy.

Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration.

G Milano, G. Milano, J. Fischel, 1992, European journal of cancer.

Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression

Dominique Grall, I. Fantozzi, A. Bozec, 2008, Acta oncologica.

Sequence studies on the 5S RNA of Proteus vulgaris: comparison with 5S RNA of Escherichia coli.

J. Ebel, J. Fischel, 1975, Biochimie.

The combination of docetaxel and the somatostatin analogue lanreotide on androgen‐independent docetaxel‐resistant prostate cancer: experimental data

G. Milano, M. Merlano, J. Fischel, 2008, BJU international.

Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation

Laetitia Padovani, Joseph Ciccolini, A. Bozec, 2005, Molecular Cancer Therapeutics.

Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2011, Oral oncology.